ATE369857T1 - Methode zur stabilisierung von benzimidazol- verbindungen - Google Patents

Methode zur stabilisierung von benzimidazol- verbindungen

Info

Publication number
ATE369857T1
ATE369857T1 AT00969905T AT00969905T ATE369857T1 AT E369857 T1 ATE369857 T1 AT E369857T1 AT 00969905 T AT00969905 T AT 00969905T AT 00969905 T AT00969905 T AT 00969905T AT E369857 T1 ATE369857 T1 AT E369857T1
Authority
AT
Austria
Prior art keywords
stabilizing
benzimidazole compounds
benzimidazole
acceptable salt
physiologically acceptable
Prior art date
Application number
AT00969905T
Other languages
English (en)
Inventor
Koji Ukai
Satoshi Fujioka
Mitsuru Mizuno
Makoto Yokoyama
Shigeru Aoki
Masao Kawamura
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE369857T1 publication Critical patent/ATE369857T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00969905T 1999-10-20 2000-10-19 Methode zur stabilisierung von benzimidazol- verbindungen ATE369857T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29806399 1999-10-20

Publications (1)

Publication Number Publication Date
ATE369857T1 true ATE369857T1 (de) 2007-09-15

Family

ID=17854666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969905T ATE369857T1 (de) 1999-10-20 2000-10-19 Methode zur stabilisierung von benzimidazol- verbindungen

Country Status (19)

Country Link
US (1) US7220762B1 (de)
EP (1) EP1222922B1 (de)
JP (1) JP4081273B2 (de)
KR (1) KR20020038759A (de)
CN (1) CN1197574C (de)
AT (1) ATE369857T1 (de)
AU (1) AU782538B2 (de)
CA (1) CA2387746C (de)
CY (1) CY1107506T1 (de)
DE (1) DE60036014T2 (de)
DK (1) DK1222922T3 (de)
ES (1) ES2288876T3 (de)
HU (1) HU229213B1 (de)
MX (1) MXPA02003762A (de)
NO (1) NO329940B1 (de)
PT (1) PT1222922E (de)
RU (1) RU2259828C2 (de)
TW (1) TWI268779B (de)
WO (1) WO2001028559A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
BR0214372A (pt) * 2001-11-21 2004-10-26 Eisai Co Ltd Composição de um preparado contendo um composto ácido-instavel fisiologicamente ativo e processo para a produção da mesma
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
WO2004003908A1 (en) 2002-06-28 2004-01-08 Lg Electronics Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
WO2008129517A2 (en) * 2007-04-23 2008-10-30 Ranbaxy Laboratories Limited A stabilized delayed release pharmaceutical composition of rabeprazole
JP5399749B2 (ja) * 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
JP2015522653A (ja) 2012-07-26 2015-08-06 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ プロトンポンプ阻害剤の医薬組成物
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB189698A (en) 1921-12-29 1922-12-07 Miniere & Ind Franco Bresilien Method for the treatment of monazite and other phosphate ores
US4471638A (en) * 1982-03-26 1984-09-18 Steelcase Inc. Front removable lock
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
ZA871177B (en) 1986-02-21 1988-10-26 Nihon Nohyaku Co Ltd 1,3-diketone derivatives and their use
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH0656665A (ja) 1992-08-03 1994-03-01 Nippon Chemiphar Co Ltd イミダゾール誘導体を含有する胃溶性抗潰瘍剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
BR9506018A (pt) 1994-07-08 1997-09-02 Astra Ab Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
DK1092434T3 (da) * 1995-09-21 2004-07-26 Pharma Pass Ii Llc Hidtil ukendt sammensætning indeholdende lansoprazol og fremgangsmåde til fremstilling deraf
BE1009764A3 (nl) 1995-11-06 1997-08-05 Dsm Nv Werkwijze voor de bereiding van een alpha-alkylkaneelaldehyde.
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
JPH09216817A (ja) 1996-02-08 1997-08-19 Amano Pharmaceut Co Ltd 防湿性且つ易水崩壊性コーティング製剤
DE69713948D1 (de) 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
CA2248784A1 (en) 1996-06-25 1997-12-31 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use
GB9710800D0 (en) 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
TW580397B (en) 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
SE9702000D0 (sv) 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
ZA9810765B (en) 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same

Also Published As

Publication number Publication date
CY1107506T1 (el) 2013-03-13
CA2387746C (en) 2010-06-29
AU7950200A (en) 2001-04-30
JP4081273B2 (ja) 2008-04-23
US7220762B1 (en) 2007-05-22
RU2259828C2 (ru) 2005-09-10
EP1222922A4 (de) 2006-04-12
TWI268779B (en) 2006-12-21
NO20021875D0 (no) 2002-04-19
CN1197574C (zh) 2005-04-20
HUP0203333A3 (en) 2004-01-28
EP1222922A1 (de) 2002-07-17
DK1222922T3 (da) 2007-12-03
HU229213B1 (en) 2013-09-30
MXPA02003762A (es) 2002-09-30
NO20021875L (no) 2002-06-04
WO2001028559A1 (fr) 2001-04-26
HUP0203333A2 (hu) 2003-02-28
KR20020038759A (ko) 2002-05-23
CN1382049A (zh) 2002-11-27
CA2387746A1 (en) 2001-04-26
NO329940B1 (no) 2011-01-24
ES2288876T3 (es) 2008-02-01
PT1222922E (pt) 2007-09-12
DE60036014T2 (de) 2008-04-30
DE60036014D1 (de) 2007-09-27
AU782538B2 (en) 2005-08-04
EP1222922B1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
ATE369857T1 (de) Methode zur stabilisierung von benzimidazol- verbindungen
EP1306375A4 (de) Salze von benzimidazol-derivaten und deren verwendung
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
DK1200418T3 (da) Nematodicide trifluorbutener
EP0931788A3 (de) Metalloproteinase-Inhibitoren
EP1191025A4 (de) Kristalle von benzimidazolderivaten
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
ATE306925T1 (de) Minoxidil enthaltende zubereitung
RS50071B (sr) Novi oblik soli pantoprazola
IT1311922B1 (it) Composti farmaceutici.
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
PT1578741E (pt) Compostos aromáticos como agentes antiinflamatórios, imunoreguladores e antiproliferativos
ES551886A0 (es) Procedimiento para la obtencion de s.s -dioxido de 3-acetilamino-4-metoxi-benzoisotiazol
DK1619185T3 (da) 4,4-difluor-1,2,3,4-tetrahydro-5H-1-benzazepinderivat eller salt deraf
ATE205835T1 (de) Akarizid und insektizid wirksame, substituierte pyrimidine und verfahren zu ihrer herstellung
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1222922

Country of ref document: EP